MIG Capital Initiates CHF 7.75 Million Investment in ASTRA Therapeutics

MIG Capital, a prominent German venture capital firm, announced a CHF 7.75 million seed financing for ASTRA Therapeutics. The Swiss start-up, based in Villigen, focuses on precision drugs targeting eukaryotic pathogens. MIG Capital allocates CHF 3 million through its MIG Fonds, joined by U.S. firm Digitalis Ventures and others like Borealis Ventures.

ASTRA Therapeutics, founded in 2022, develops Parabulins® to manage parasitic infections without harming hosts. These innovations target veterinary market needs due to rising drug resistance. The global parasiticide market is valued at over $10 billion, with significant unmet demand.

The investment positions ASTRA to address drug resistance, leveraging its innovative ParaX® platform. MIG Capital recognizes the commercial potential in ASTRA’s novel approach and sees a strategic opportunity to expand in veterinary medicine.